MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a value of the control of

Times one require	ed to respond to a collection of illicontent	
Under the Paperwork Reduction Act of 1995, no persons are require		APR 2 7 2004
Substitute for form 1449B/P10	Application Number 10/777,144 02/13/2004	E S
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date  First Named Inventor  Group Art Unit  Unassigned  Joseph SCHLESSINGE  Unassigned  July  Joseph SCHLESSINGE  Unassigned  July  July	
(use as many sheets as necessary)	Attorney Docket Number 034536-1210	
Cheet		

				FO	REIGN PATENT DOCUMENT	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner	Cite No.1	Office	oreign Patent Docum	Code	Name of Patentee or Applicant of Cited Documents	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	To
nitials*	140.			known)	NEW YORK UNIVERSITY	01-23-1992		+
	A1	wo	92/01050	_	NATIONAL UNIVERSITY	01-20-1994		
8/	A2	wo	94/01119	A1	OF SINGAPORE	01-20-100 !		+
₩ <u></u>	<b></b>	<b></b>		_	FAMITALIA CARLO ERBA	02-17-1994		
V	A3	wo	94/03610	A2	S.R.L.			
	<del> </del>		-		NEW YORK UNIVERSITY	04-28-1994		
1	A4	wo	94/09037	A1	NEW YORK UNIVERSITY MEDICAL CENTER	04-28-1994		لـ

VD/				
			MON PATENT LITERATURE DOCUMENTS  me of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	T <sup>6</sup>
Examiner Initials*	Cite No.1	Harm (hook	me of the author (in CAPITAL LETTERS), title of the article (when appropriate), fille of the me of the author (in CAPITAL LETTERS), title of the article (when appropriate), fille of the order of the author (in CAPITAL LETTERS), title of the article (when appropriate), fille of the article (when appropriate), volume-issue number(s), fille of the article (when appropriate), fille of the article (when appr	
	A5	663-704 (190	// heaphotyrosyl protein phosphatase from the	
	A6	AA31 human	epiderillois and a role in	
<b>%</b>	A7	mornhogene	SIS also placetory	
9/	A8	1 Oct. 1900, I	p. 7400 7 151 acquence and	
	A9	relationship	to a family even antigen (CD45): A putative receptor-linked protein tyrosine	1
	A10	CHARBON phosphata	NEAU et al., "The leukocyte common analysis (1988) se," <u>Proc. Natl. Acad. Sci. USA</u> 85:7182-7188 (1988) se," <u>Proc. Natl. Acad. Sci. USA</u> 85:7182-7188 (1988) se," <u>Proc. Natl. Acad.</u> Feet al., "Cloning of a cDNA for a major human protein-tyrosine-phosphatase," <u>Proc. Natl. Acad.</u>	1
	A1	CHERNOR	F et al., "Cloning of a cDNA for a major nome," per 87:2735-2739 (1990)	_1

		Date	1/31/0-6
	<i>M</i>	Considered	7 6
Examiner	Whether or not citation is in conformance with MPEP 809.	Draw line through citation if	not in conformance and not
Signature	whether or not citation is in conformance with the		Luca ando (MIPO)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>6</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the their statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the their statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the chief information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the Informati

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute fo	r form 1449B	/PTO	Complete if Known			
	INFORMATI	ON DISCLO	SURE	Application Number	10/777,144		
	STATEMEN	T BY APPLI	ICANT	Filing Date	02/13/2004		
				First Named Inventor	Joseph SCHLESSINGER		
			•	Group Art Unit	Unassigned 1644		
(use as many sheets as necessary)			cessary)	Examiner Name	Unassigned SANJOO JALLA		
Sheet	2	of	6	Attorney Docket Number	034536-1210		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	⊤®
	A12	CHURCH, et al., "Genomic Sequencing", <u>Proc. Natl. Acad. Sci.</u> , vol. 81, pp. 1994-1995, (1984)	
	A13	COOL et al., "cDNA isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family," Proc. Natl. Acad. Sci, USA 86:5257-5261 (1989)	
	A14	COOL et al., "Overexpression of a T-cell protein tyrosine phosphatase (PTPase) in BHK Cells," <u>FASEB J.</u> 4:A2078 (abstr. 2230) (1990)	
	A15	CYERT and THORNER, "Putting it on and taking if off: Phosphoprotein phosphatase involvement in cell cycle regulation," Cell 57:891-893 (1989)	
	A16	DAUM et al., "Characterization of a human recombinant receptor-linked protein tyrosine phosphatase," <u>J. Biol, Chem.</u> , 266:12211-12215 (1991)	
	A17	FISCHER et al., "Protein tyrosine phosphatases: A diverse family of intracellular and transmembrane enzymes," Science 253:401-406 (1991)	
·	A18	GEBBINK et al., "Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase," FEBS Lett. 290:123-130 (1991)	
	A19	GEORGE and PARKER, "Preliminary characterization of phosphotyrosine phosphatase activities in human peripheral blood lymphocytes: Identification of CD45 as a phosphotyrosine phosphatase," <u>J. Cell Biochem.</u> 42:71-81 (1990).	
	A20	GU et al., "Identification, cloning, and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1," <u>Proc. Natl. Acad. Sci. USA</u> 88:5867-5871 (1991)	
<b>&amp;</b> /	A21	GUAN et al., "Protein Tyrosine Phosphatase Activity of an Essential Virulence Determinant in Yersinia," Science, Aug. 3, 1990, pp. 553-556, vol. 249.	
	A22	GUAN et al., "Cloning and expression of a protein-tyrosine-phosphatase," Proc. Natl. Acad. Sci. USA 87:1501-1505 (1990)	
	A23	HALL et al., "Complete exon-intron organization of the human leukocyte common antigen (CD45) gene," <u>J. Immunol.</u> 141:2781-2787 (1988)	
	A24	HARIHARAN et al., "Cloning and characterization of a receptor-class phosphotyrosine phosphatase gene expressed on central nervous system axons in Drosophila melanogaster," <a href="Proc. Natl. Acad. Sci. USA">Proc. Natl. Acad. Sci. USA</a> 88:11266-11270 (1991)	

Examiner Signature	0	Date Considered	1/31/06	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>1</sup> Unique citation designation number. 2See attached Kinds of U.S. Patent Documents, 3Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English tanguage Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute fo	or form 1449E	S/PTO		Complete if Known
	INFORMATI	ON DISCLO	SURE	Application Number	10/777,144
	STATEMEN	T BY APPL	ICANT	Filing Date	02/13/2004
				First Named Inventor	Joseph SCHLESSINGER
				Group Art Unit	Unassigned /644
	(use as many s	sheets as ne	ecessary)	Examiner Name	Unassigned SANTOD JALLA
Sheet	3	of	6	Attorney Docket Number	034536-1210

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
	A25	HUNTER, "Protein-tyrosine phosphatases: The other side of the coin," Cell 58:1013-1016 (1989)	
	A26	JIRIK et al., "Cloning and chromosomal assignment of a widely expressed human receptor-like protein-tyrosine phosphatase," FEBS Lett. 273:239-242 (1990)	
	A27	JIRIK et al., "Cloning of a novel receptor-linked protein tyrosine phosphatase from a human hepatoblastoma cell line," <u>FASEB J.</u> 4A:2082 (Abstr. 2253) (1990)	
	A28	JONES et al., "Phosphotyrosyl-protein phosphatases," <u>J. Biol. Chem.</u> 264:7747-7753 (1989)	
	A29	KAPLAN et al., "Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain," <u>Proc. Natl. Acad. Sci. USA</u> 87:7000-7004 (1990)	
	A30	KIENER and MITTLER, "CD45-protein tyrosine phosphatase cross-linking inhibits T-cell receptor CD3-mediated activation in human T-cells," <u>J. Immunol.</u> 143:23-28 (1989)	
	A31	KLARLUND, "Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins," Cell 41:707-717 (1985)	
8	A32	KRUEGER and SAITO, "A human transmembrane protein-tyrosine-phosphatase, PTP, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, pp. 7417-7421, vol. 89, No. 16.	
	A33	KRUEGER et al., "Structural diversity and evolution of human receptor-like protein tyrosine phosphatases," <u>EMBO J.</u> 9:3241-3252 (1990)	
	A34	LEVY et al., "The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system," <u>Journal of Biological Chemistry</u> , May 15, 1993, pp. 10573-10581, vol. 268, No. 14	
	A35	LOMBROSO et al., "Molecular characterization of a protein-tyrosine-phosphatase enriched in striatum," Proc. Natl. Acad. Sci. USA 88:7242-7246 (1991)	
	A36	MATTHEWS et al., "Characterization of hemotopoietic intracellular protein tyrosine phosphatases: Description of a phosphatase containing an SH2 Domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences," Molec. and Cell. Biol. 12:2396-2405 (1992)	

Examiner	0 /	Date	1/2/106
Signature	9	Considered	1/3/100

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not/citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form	1449B/	PTO	Complete if Known			
	INFORMATION DI	SCLO	SURE	Application Number	10/777,144		
	STATEMENT BY APPLICANT			Filing Date	02/13/2004		
				First Named Inventor	Joseph SCHLE	SSINGER	
				Group Art Unit	Unassigned	1644	
(use as many sheets as necessary)				Examiner Name	Unassigned	CANJOO JALLA	
Sheet	4	of	6	Attorney Docket Number	034536-1210		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>®</sup>
	A37	MATTHEWS et al., "Identification of an additional member of the protein-tyrosine-phosphatase family: Evidence for alternative splicing in the tryosine phosphatase domain," <u>Proc. Natl. Acad. Sci. USA</u> 87:4444-4448 (1990)	
	A38	MUSTELIN et al., "Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase," Proc. Natl. Acad. Sci. USA 86:6302-6306 (1989)	
	A39	OHAGI et al., "Sequence of a cDNA encoding human LRP (leukocyte common antigen-related peptide)," Nucl. Acids Res. 18:7159 (1990)	
	A40	OSTERGAARD et al., "Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines," <u>Proc. Natl. Acad. Sci. USA</u> 86:8959-8963 (1989)	
	A41	PALLEN et al., "Purification of a phosphotyrosine phosphatase that dephosphorylates the epidermal growth factor receptor autophosphorylation sites," <u>Ann. N.Y. Acad. Sci.</u> 551:299-308 (1988)	
	A42	PINGEL and THOMAS, "Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation," Cell 58:1055-1065 (1989)	
	A43	PLUTZKY et al., "Isolation of a src homology 2-containing tyrosine phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 89:1123-1127 (1992)	
	A44	POT and DIXON, "A thousand and two protein tyrosine phosphatases," <u>Biochem. Biophys. Acta.</u> 1136:35-43 (1992)	
	A45	RALPH et al., "Structural variants of human T200 glycoprotein (leukocyte-common antigen)," <u>EMBO J.</u> 6:1251-1257 (1987)	
8	A46	SAIKI et al., "Enzymatic amplification of .betaglobin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia," SCIENCE, Dec. 20, 1985, pp. 1350-1354, vol. 230	
`	A47	SAP et al., "Cloning and expression of a widely expressed receptor tyrosine phosphatase," <u>Proc. Natl. Acad. Sci. USA</u> 87:6112-6116 (1990)	
8	A48	SCOPES, <u>Protein Purification: Principles and Practice</u> , Springer-Verlag, New York, 1987, TABLE OF CONTENTS ONLY	
	A49	SHEN et al., "A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases," Nature 352:736-739 (1991)	

Examiner Signature	8	Date Considered	1/31/06

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO			/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	10/777,144			
		Filing Date	02/13/2004			
		First Named Inventor	Joseph SCHLESSINGER			
		Group Art Unit	Linessigned 1644			
		Examiner Name	Unassigned (AN JOO JALLA			
Sheet	5	of	6	Attorney Docket Number	034536-1210	

		NON PATENT LITERATURE DOCUMENTS	20.19
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	٦⁴
	A50	STREULI et al., "A family of receptor-linked protein tyrosine phosphatases in humans and Drosophila," Proc. Natl. Acad. Sci. USA 86:8698-8702 (1989)	
	A51	STREULI et al., "A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen," <u>J. Exp. Med.</u> 168:1523-1530 (1988)	
	A52	STREULI et al., "Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens," <u>J. Exp. Med.</u> 166:1548-1566 (1987)	
	A53	STREULI et al., "Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases LCA and LAR," <a href="EMBO Journal">EMBO Journal</a> 9:2399-2407 (1990)	
·	A54	THOMAS et al., "ABA, A novel member of the tyrosine phosphatase family," <u>FASEB J.</u> 4:A2078 (Abstr. 3140) (1990)	
	A55	THOMAS, "The leukocyte common antigen family," Ann. Rev. Immunol. 7:339-369 (1989)	
	A56	TONKS and CHARBONNEAU, "Protein tyrosine dephosphorylation and signal transduction," <u>Trends in Biochem. Sci.</u> 14:497-500 (1989)	
	A57	TONKS et al., "CD45, an integral membrane protein tyrosine phosphatase," <u>J. Biol. Chem.</u> 265:10674-10680 (1990)	
	A58	TONKS et al., "Demonstration that the leukocyte common antigen CD45 is a protein tyrosine phosphatase," Biochemistry 27:8695-8701 (1988)	
	A59	TONKS et al., "Purification of the major protein-tyrosine-phosphatases of human placenta," <u>J. Biol. Chem.</u> 263:6722-6730 (1988)	
	A60	TOWBIN, et al., "Electrophoretic Transfer of Proteins From Polyacrylamide Gels To Nitrocellulose Sheets: Procedure And Some Applications", <u>Proc. Natl. Acad. Sci.</u> , vol. 76, No. 9, pp. 4350-4354, (1979)	
	A61	TSAI et al., "Isolation and characterization of temperature-sensitive and thermostable mutants of the human receptor-like protein tyrosine phosphatase LAR," <u>J. Biol. Chem.</u> 266(16):10534-10543 (1991)	
	A62	YANG and TONKS, "Isolation of a cDNA clone encoding a human protein-tyrosine phosphatase with homology to the cytoskeletal-associated proteins band 4.1, ezrin, and talin," <a href="Proc. Natl. Acad. Sci. USA">Proc. Natl. Acad. Sci. USA</a> 88:5949-5953 (1991)	

Examiner Signature	B	Date Considered	1/34/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>1</sup> Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Output

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are require	Complete if Known
Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number 10/777,144  Filing Date 02/13/2004  First Named Inventor Joseph SCHLESSINGER  Group Art Unit Unassigned 1644  Group Art Unit Unassigned SAN 700 JAMA
(use as many sheets as necessary) Sheet 6 of 6	Examiner Name  Attorney Docket Number 034536-1210

		NON PATENT LITERATURE DOCUMENTS	T <sup>6</sup>
	Cito	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), item (book, magazine, journal, serial, symposium, catalog, etc.)	4
xaminer hitials*	Cite No. <sup>1</sup>	publisher, city and/or country who be publisher, city and/or country who be publisher.	
Af	A63		
	A64	(1992)  ZHENG, et al., "Cell Transformation and Activation of pp60 .sup.c-src By Overexpression of a Protein Tyrosine Phophatase," Nature, vol. 359, No. 6393, pp. 336-339 (1992)	
	-		-
	+		+-
	-		+
	-		+
	+		+
-	-		+
-	-		+
-	-		$\dashv$
-	+		-
-			+
-	-+		
-			

		Date Considered	1/31/06	ļ
Examiner Signature	whether or not citation is in conformance with MPE	609. Draw line through citation	on if not in conformance and not	
Signistary	the there or not citation is in como		ORDAN	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>\*</sup>Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

English ranguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the amount of time you are required to Complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, and the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, PO Box 1450, and the Information Officer (Information Officer) and Information Officer (Information Officer) and Information Officer (Informatio